ORCID Profile
0000-0002-1108-3863
Current Organisations
UNSW Sydney
,
ARC Centre for Excellence in Population Ageing Research
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 2020
Publisher: JMIR Publications Inc.
Date: 25-01-2018
DOI: 10.2196/MHEALTH.7849
Publisher: BMJ
Date: 11-2022
DOI: 10.1136/BMJOPEN-2022-064641
Abstract: To measure the disease burden of ageing based on age-related diseases (ARDs), the sex and regional disparities and the impact of health resources allocation on the burden in China. A national comparative study based on Global Burden of Diseases Study estimates and China’s routine official statistics. Thirty-one provinces of Mainland China were included for analysis in the study. No in iduals were involved. We first identified the ARDs and calculated the disability-adjusted life years (DALYs) of ARDs in 2016. We assessed the ARD burden disparities by province and sex and calculated the provincial ARD burden-adjusted age. We assessed historical changes between 1990 and 2016. Fixed effects regression models were adopted to evaluate the impact of health expenditures and health workforce indicators on the ARD burden in 2010–2016. In 2016, China’s total burden of ARDs was 15 703.7 DALYs (95% uncertainty intervals: 12 628.5, 18 406.2) per 100 000 population. Non-communicable diseases accounted for 91.9% of the burden. There were significant regional disparities. The leading five youngest provinces were Beijing, Guangdong, Shanghai, Zhejiang and Fujian, located on the east coast of China with an ARD burden-adjusted age below 40 years. After standardising the age structure, western provinces, including Tibet, Qinghai, Guizhou and Xinjiang, had the highest burden of ARDs. Males were disproportionately affected by ARDs. China’s overall age-standardised ARD burden has decreased since 1990, and females and eastern provinces experienced the largest decline. Regression results showed that the urban–rural gap in health workforce density was positively associated with the ARD burdens. Chronological age alone does not provide a strong enough basis for appropriate ageing resource planning or policymaking. In China, concerted efforts should be made to reduce the ARDs burden and its disparities. Health resources should be deliberately allocated to western provinces facing the greatest health challenges due to future ageing.
Publisher: BMJ
Date: 06-2020
DOI: 10.1136/BMJGH-2020-002306
Abstract: China has the highest number of hepatitis B and C cases globally. Despite remarkable achievements, China faces daunting challenges in achieving international targets for hepatitis elimination. As part of a large-scale project assessing China’s progress in achieving health-related Sustainable Development Goals using quantitative, qualitative data and mathematical modelling, this paper summarises the achievements, gaps and challenges, and proposes options for actions for hepatitis B and C control. China has made substantial progress in controlling chronic viral hepatitis. The four most successful strategies have been: (1) hepatitis B virus childhood immunisation (2) prevention of mother-to-child transmission (3) full coverage of nucleic acid lification testing in blood stations and (4) effective financing strategies to support treatment. However, the total number of deaths due to hepatitis B and C is estimated to increase from 434 724 in 2017 to 527 829 in 2030 if there is no implementation of tailored interventions. Many health system barriers, including a fragmented governance system, insufficient funding, inadequate service coverage, unstandardised treatment and flawed information systems, have compromised the effective control of hepatitis B and C in China. We suggest five strategic priority actions to help eliminate hepatitis B and C in China: (1) restructure the viral hepatitis control governance system (2) optimise health resource allocation and improve funding efficiency (3) improve access to and the quality of the health benefits package, especially for high-risk groups (4) strengthen information systems to obtain high-quality hepatitis epidemiological data (5) increase investment in viral hepatitis research and development.
Publisher: Elsevier BV
Date: 06-2020
Location: Australia
No related grants have been discovered for Shu Chen.